Aldeyra Therapeutics, Inc.
About Aldeyra Therapeutics, Inc.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma, and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Net income
- -$33.8M
- Total assets
- $72.1M
- Market cap
- $98.3M
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Operating income
- -$35.3M
- Income tax
- $0
- Net income
- -$33.8M
- EPS (basic)
- $-0.56
- EPS (diluted)
- $-0.56
Balance sheet
- Total assets
- $72.1M
- Current assets
- $71.8M
- Total liabilities
- $27.8M
- Current liabilities
- $27.8M
- Shareholders’ equity
- $44.3M
Cash flow
- Operating cash flow
- -$33.3M
- Investing cash flow
- $47.7M
- Financing cash flow
- $1.1M
- Net cash flow
- $15.5M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $98.3M
- EPS (diluted)
- $-0.56
- Shares outstanding
- 58.2M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- May 2, 2014
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $33.8M.
- Trading 71% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Aldeyra Therapeutics, Inc..
Write a review
News about Aldeyra Therapeutics, Inc.
News & sentiment via Polygon.io
